Dennis Slamon/cancerhistoryproject.com
Mar 20, 2025, 17:47
Dennis Slamon on the pioneering work behind Herceptin’s FDA approval – NFCR
National Foundation for Cancer Research (NFCR) shared a post on LinkedIn:
“Understanding HER-2 the key to breast cancer subtypes.
From groundbreaking research to life-saving impact, Dr. Dennis Slamon joins NFCR CEO Dr. Sujuan Ba to discuss the pioneering work and collaboration that led to the eventual FDA approval of Herceptin, and what’s next in cancer research.
Listen now:
Proceed to the video attached to the post.
More posts featuring NFCR.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 2, 2025, 09:30
Aug 2, 2025, 09:25
Aug 2, 2025, 09:21
Aug 2, 2025, 08:55
Aug 2, 2025, 08:54
Aug 2, 2025, 08:32